Registry of adult patients with atrial fibrillation in China
Chinese Atrial Fibrillation Registry
This study is creating a long-term registry of adults with atrial fibrillation in China to see how different treatments work and how they affect patients' lives.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Beijing Anzhen Hospital Academic / other |
| Locations | 2 sites (Beijing, Beijing Municipality and 1 other locations) |
| Trial ID | NCT06987825 on ClinicalTrials.gov |
What this trial studies
This prospective, observational cohort study aims to create a long-term registry of adult patients with atrial fibrillation (AF) in China. It will collect standardized clinical data from over 30 hospitals to characterize patient profiles and evaluate real-world management and outcomes. The study will assess the effectiveness and safety of various AF treatment strategies and identify factors influencing therapeutic outcomes. Participants will undergo regular follow-ups to monitor heart rhythm, treatment updates, and quality of life assessments.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with documented atrial fibrillation episodes lasting more than 30 seconds.
Not a fit: Patients with atrial fibrillation due to reversible causes or those with comorbid conditions limiting life expectancy to less than one year may not benefit from this study.
Why it matters
Potential benefit: If successful, this registry could enhance the understanding and management of atrial fibrillation, leading to improved patient outcomes.
How similar studies have performed: Other observational registries have shown success in improving understanding and management of atrial fibrillation, making this approach both relevant and tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age ≥ 18 years; 2. Documented atrial fibrillation episode lasting \>30 seconds confirmed by electrocardiogram (ECG), Holter monitor, implantable cardiac monitor, or wearable ECG device 3. Signed informed consent and willingness to participate in follow-up Exclusion Criteria: 1. Atrial fibrillation due to a reversible cause (e.g., transient secondary AF) 2. Presence of comorbid conditions associated with an expected life expectancy of less than 1 year
Where this trial is running
Beijing, Beijing Municipality and 1 other locations
- Beijing Anzhen Hospital — Beijing, Beijing Municipality, China (Recruiting)
- Sir Run Run Shaw Hospital, Zhejiang University School of Medicine — Hangzhou, Zhejiang, China (Recruiting)
Study contacts
- Principal investigator: Changsheng Ma, MD — Beijing Anzhen Hospital
- Study coordinator: Liu He, PhD
- Email: theliu@139.com
- Phone: +86 13810720787
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.